Showing 15 posts of 66 posts found.


Valeant’s psoriasis drug “difficult to assess”, according to FDA staff

July 18, 2016
Research and Development, Sales and Marketing FDA, Valeant, psoriasis

Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …


Eli Lilly gets European marketing authorisation for psoriasis drug

April 26, 2016
EC, EU, Eli Lilly, drug trial, psoriasis, regulation

US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …


Vitae Pharma soars on positive mid-stage trial results for psoriasis drug

March 17, 2016
Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research

Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …


AbbVie pays $595m upfront for experimental Boehringer psoriasis drug

March 8, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, BI 655066, Boehringer Ingelheim, psoriasis

AbbVie is betting big on the future of an experimental psoriasis drug, paying $595m upfront for the rights to Boehringer …


Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials

March 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis

Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …


CHMP recommends Lilly psoriasis drug for approval

February 29, 2016
Research and Development Eli Lilly, Taltz, psoriasis

Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …


Novartis psoriasis drug shows three-year efficacy

October 12, 2015
Cosentyx, EADV, Novartis, Secukinumab, psoriasis

Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …

Stelara image

NICE U-turn on Janssen arthritis drug

June 4, 2015
Sales and Marketing Janssen, NICE, Stelara, psoriasis, uturn

NICE has performed a U-turn on Janssen’s Stelara and has now recommended the drug for the treatment of psoriatic arthritis. …

Amgen image

Amgen pulls out of psoriasis deal with AstraZeneca

May 26, 2015
Sales and Marketing Amgen, AstraZeneca, psoriasis

Amgen has ended its agreement with AstraZeneca to develop a new biologic for psoriasis, because of the likelihood of ‘restrictive …

Pfizer, Novartis and Celgene among late-stage psoriasis trial advances

March 23, 2015
Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib

Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …

AZ image

AstraZeneca enters autoimmune diseases pact with Orca

February 25, 2015
Research and Development, Sales and Marketing AstraZeneca, autoimmune, orca, orphan nuclear receptor gamma inhibitors, psoriasis, retinoic

AstraZeneca has signed a three-year research deal with the UK-based biotech firm Orca to develop treatments for autoimmune diseases. The …

Sanofi image

Sanofi enters autoimmune diseases pact with Lead Pharma

February 18, 2015
Research and Development, Sales and Marketing Sanofi, autoimmune, biox, lead pharma, psoriasis

Sanofi is to collaborate with Dutch biotech firm Lead Pharma to develop treatments for autoimmune diseases. The companies will work …

Novartis image

Novartis gets FDA approval for psoriasis drug

January 22, 2015
Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis

The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …

Abbvie image

AbbVie highlights treatment adherence

June 12, 2014
Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis

Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …

pfizer image

Mixed tale for Pfizer psoriasis drug

October 11, 2013
Sales and Marketing Enbrel, Pfizer, psoriasis, tofacitinib

Pfizer has seen its novel, oral Janus kinase (JAK) inhibitor tofacitinib turn in a mixed showing in late-stage trials in …

Latest content